Profile data is unavailable for this security.
About the company
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
- Revenue in USD (TTM)0.00
- Net income in USD-18.35m
- Incorporated2008
- Employees21.00
- LocationTheriva Biologics Inc9605 Medical Center Drive, Suite 270ROCKVILLE 20850United StatesUSA
- Phone+1 (734) 332-7800
- Fax+1 (734) 332-7878
- Websitehttps://therivabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enveric Biosciences Inc | 0.00 | -17.46m | 6.75m | 7.00 | -- | 1.30 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Cingulate Inc | 0.00 | -21.21m | 6.77m | 15.00 | -- | -- | -- | -- | -32.59 | -32.59 | 0.00 | -0.1109 | 0.00 | -- | -- | 0.00 | -199.61 | -- | -465.62 | -- | -- | -- | -- | -- | -- | -26.60 | 1.03 | -- | -- | -- | 14.65 | -- | -- | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 7.00m | 207.00 | -- | -- | -- | 1.71 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 7.01m | 9.00 | -- | 0.3315 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -18.35m | 7.17m | 21.00 | -- | 0.1939 | -- | -- | -1.15 | -1.15 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -28.88 | -36.95 | -32.40 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -28.74m | 7.18m | 38.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.0241 | 0.00 | -- | -- | 0.00 | -284.51 | -- | -- | -- | -- | -- | -- | -- | -- | -25.25 | 1.25 | -- | -89.98 | -- | -132.57 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -15.51m | 7.21m | 8.00 | -- | 0.308 | -- | -- | -12.83 | -13.18 | 0.00 | 22.46 | 0.00 | -- | -- | 0.00 | -43.50 | -- | -46.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -7.00m | 7.26m | 4.00 | -- | 0.7292 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 7.27m | 389.00 | 0.0013 | 0.0001 | 0.7877 | 0.1276 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 7.39m | 8.00 | -- | 1.74 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Pulmatrix Inc | 7.30m | -14.12m | 7.41m | 22.00 | -- | 0.412 | -- | 1.02 | -3.87 | -3.87 | 2.00 | 4.93 | 0.1948 | -- | 6.56 | 331,727.30 | -37.70 | -46.91 | -42.80 | -58.12 | -- | -- | -193.49 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 7.42m | 5.00 | -- | 0.1396 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.44m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 14.81k | -13.43m | 7.45m | 12.00 | -- | 0.8145 | -- | 502.98 | -0.8147 | -0.8147 | 0.0008 | 0.3468 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 7.50m | 23.00 | -- | -- | -- | 2.40 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Intelligent Bio Solutions Inc | 2.46m | -13.40m | 7.57m | 17.00 | -- | 0.0997 | -- | 3.08 | -131.37 | -131.37 | 20.91 | 26.67 | 0.1831 | 2.41 | 9.09 | 144,726.50 | -99.96 | -80.65 | -157.15 | -224.84 | 20.90 | -- | -545.95 | -948.54 | 0.3864 | -- | 0.1602 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Theriva Biologics Inc's reporting currency: US Dollar USD
5.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 366.58k | 2.14% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 190.06k | 1.11% |
| Geode Capital Management LLCas of 31 Dec 2023 | 141.17k | 0.82% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 59.21k | 0.35% |
| Citadel Securities LLCas of 31 Dec 2023 | 57.95k | 0.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 48.69k | 0.28% |
| Jane Street Capital LLCas of 31 Dec 2023 | 47.56k | 0.28% |
| Virtu Americas LLCas of 31 Dec 2023 | 39.12k | 0.23% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 28.53k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 26.60k | 0.16% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
